Overview

A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer

Status:
Unknown status

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This study is a multicentre, open label, non-randomized phase I study. The main objectives of the study are to determine the pharmacokinetic profile of the drug at different dose levels in the patients with Advanced Breast Cancer. Maximum Tolerated Dose (MTD) and safety of Paclitaxel Nanoparticle will also be simultaneously assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Fresenius Kabi Oncology Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel